[Inflammation, bronchial hyperreactivity and mucoviscidosis].
Inflammation aggravates respiratory impairment in patients with cystic fibrosis. It plays an essential role in the genesis of bronchial hyperreactivity. Corticosteroids are the predominant therapeutic agents used. The importance of bronchial hyperreactivity in cystic fibrosis is correlated with disease severity. Treatment is essential to slow down the progression of bronchiopulmonary involvement.
Derelle
J
J
Hôpital d'enfants, Vandoeuvre-les-Nancy, France.
D016535:Bronchial Hyperreactivity / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D001991:Bronchitis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male
Inflammation, hyperréactivité bronchique et mucoviscidose.